Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer / 癌症
Chinese Journal of Cancer
;
(12): 805-814, 2011.
Artigo
em Inglês
| WPRIM
| ID: wpr-294456
ABSTRACT
In the last decade, we have gained significant understanding of the mechanism by which vesicular stomatitis virus (VSV) specifically kills cancer cells. Dysregulation of translation and defective innate immunity are both thought to contribute to VSV oncolysis. Safety and efficacy are important objectives to consider in evaluating VSV as a therapy for malignant disease. Ongoing efforts may enable VSV virotherapy to be considered in the near future to treat drug-resistant ovarian cancer when other options have been exhausted. In this article, we review the development of VSV as a potential therapeutic approach for recurrent or drug-resistant ovarian cancer.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias Ovarianas
/
Patologia
/
Farmacologia
/
Fisiologia
/
Terapêutica
/
Virologia
/
Replicação Viral
/
Apoptose
/
Vírus da Estomatite Vesicular Indiana
/
Resistencia a Medicamentos Antineoplásicos
Limite:
Animais
/
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Chinese Journal of Cancer
Ano de publicação:
2011
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS